Tag: Peripheral arterial disease
Endologix announces 36-month results of DETOUR2 study
Endologix has announced the final 36-month results from the DETOUR2 study—a prospective, single-arm, international, multicentre clinical evaluation of the novel Detour system for fully...
Bolt Medical announces completion of RESTORE ATK and RESTORE BTK pivotal...
Bolt Medical has announced the completion and results of the RESTORE ATK and RESTORE BTK pivotal clinical trials investigating the company's Bolt intravascular lithotripsy...
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for...
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration...
FDA grants R3 Vascular IDE approval for ELITE-BTK pivotal trial of...
R3 Vascular today announced that the Food and Drug Administration (FDA) has granted investigational device exemption (IDE) approval to initiate its ELITE-BTK pivotal trial...
Novel RCT framework set to improve design and reporting of endovascular...
Pilot testing has shown that a new framework—dubbed Endo-STAR—can be used to describe and standardise endovascular interventions for peripheral arterial disease (PAD) within a...
New ESC guidelines combine peripheral arterial and aortic diseases for first...
The European Society of Cardiology (ESC) has today published its 2024 guidelines for the management of peripheral arterial and aortic diseases (PAAD), evaluating these...
Humacyte’s ATEV granted FDA Regenerative Medicine Advanced Therapy designation for advanced...
Humacyte recently announced it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its investigational...
Chickasaw Nation study exemplifies how diversity can boost patient access to...
A “feasible and reproducible” intervention bundle characterized by surveys, provider education and patient screening has demonstrated the potential to not only identify gaps in...
Twin global burdens of growing PAD prevalence and vascular workforce shortfall...
A growing prevalence of peripheral arterial disease (PAD) across the world parallels a deteriorating PAD landscape in the U.S., underscoring a need for more...
Toe and flow session aims to break down barriers to multidisciplinary...
If you had cancer you would go to a cancer center where you would get a multidisciplinary approach,” SVS President Joseph Mills, MD, tells...
BEST-CLI and the BASIL trials: Motion sees audience move in favor...
During the 2024 Charing Cross (CX) International Symposium in London, England (April 23–25), a Great Debate that pitted four global peripheral arterial disease (PAD)...
Paclitaxel controversy: Yes, device restrictions did cause harm
“Unfortunately, we are doing worse for our patients today,” were the sobering thoughts of Eric Secemsky (Boston, United States) during a late-breaking presentation in...
The top 10 most popular Vascular Specialist stories of March 2024
In March, the most read stories from Vascular Specialist include a new analysis which suggests of a ‘lack of reach’ of vascular voices within...
The top 10 most popular Vascular Specialist stories of February 2024
In February, the most read stories from Vascular Specialist include a study of metformin and its potential as the first-ever medical treatment that can...
LimFlow announces agreement to be acquired by Inari Medical
LimFlow announced today that it has entered into a definitive agreement to be acquired by Inari Medical.
A press release details that, under the terms...
TCT 2023: First presentation of complete patient-level dataset on paclitaxel and...
Data from a patient-level meta-analysis—a factor in the Food and Drug Administration’s (FDA) recent change of position on the use of paclitaxel-coated devices to...
TCT 2023: First presentation of complete patient-level dataset on paclitaxel and...
Data from a patient-level meta-analysis—a factor in the US Food and Drug Administration’s (FDA) recent change of position on the use of paclitaxel-coated devices...
Long-awaited FDA update finds data do not support excess mortality risk...
In a letter to healthcare providers dated July 11, 2023, the Food and Drug Administration (FDA) communicates that the risk of mortality associated with...
Sex-related disparities in lower-extremity revascularization outcomes brought into focus
Women are more likely to undergo reintervention after lower extremity revascularization for peripheral arterial disease (PAD) compared to male patients with similar limb salvage...
The top 10 most popular Vascular Specialist stories of May 2023
Last month, Vascular Specialist most piqued reader interest with a commentary from the editor-in-chief on why he supports the decision by the Southern Association for Vascular...
New ‘biopsychosocial’ roadmap set out to address PAD treatment and mental...
A recent proposal has called for “whole-person, multidisciplinary interventions” after an interrogation of the interplay between lower extremity peripheral arterial disease (PAD) and mental...
New VOYAGER PAD analysis confirms consistent benefit of low-dose rivaroxaban plus...
Data from a new prespecified analysis of the phase III VOYAGER PAD clinical trial show that low-dose rivaroxaban plus aspirin resulted in a 33%...
‘Urgent action needed’ to improve implementation of guideline-directed medical therapy for...
Almost one-half of the patients receiving a peripheral vascular intervention (PVI) in the Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) registry between...
More than a research project: The vascular trainee’s role in tackling...
One of my earliest clinical experiences with vascular disease was as a high school student shadowing at a busy urban hospital in Detroit. A...
The top 10 most popular Vascular Specialist stories in January
January’s top 10 includes “Our forever plague,” a combined editorial by Malachi Sheahan III, MD, our medical editor, on fake news and science, and...
Learn by doing at February SVS PAD workshop
The Society for Vascular Surgery (SVS) Peripheral Arterial Disease (PAD) Workshop in February will feature four hours of hands-on surgical skills training, on 10...
Hispanic adults with PAD access inpatient care most often via the...
Hispanic adults hospitalized for treatment of symptoms of peripheral arterial disease (PAD) were more likely to access this care by going to the emergency...
VIVA 2021: Consensus established for appropriate use of IVUS in peripheral...
A worldwide committee of 40 cross-specialty medical experts achieved what was hailed as the first-ever consensus for the appropriate use of intravascular ultrasound (IVUS)...
Physicians draw attention to Medicare cuts as PAD Awareness Month kicks...
A coalition of physicians and other interested parties focused on peripheral arterial disease (PAD) has called on Congress and the Centers for Medicare and...
First patients enrolled in SUPERSURG study of Supera peripheral stent system
ID3 Medical Belgium has announced the first two enrollments in the SUPERSURG study to investigate the safety and efficacy of Abbotts’ Supera peripheral stent...
Clopidogrel exposure along with aspirin and rivaroxaban should be ‘minimized or...
“More bleeding with background clopidogrel, even if not severe by adjudication, may be associated with broad consequences, including discontinuation of therapies. In the absence...